Prevention is back in the spotlight – Highlights from American Heart Association Scientific Sessions 2018

Grundy SM Stone NJ Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol 2018.

Manson JE Cook NR Lee IM et al. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. N Engl J Med Epub ahead of print 10 November 2018. DOI: 10.1056/NEJMoa1811403.

Manson JE Cook NR Lee IM et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med Epub ahead of print 10 November 2018. DOI: 10.1056/NEJMoa1809944.

Group ASC Bowman L Mafham M et al. Effects of n-3 fatty acid supplements in diabetes mellitus. N Engl J Med 2018; 379: 1540–1550.

Investigators OT Bosch J Gerstein HC et al. n-3 Fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med 2012; 367: 309–318.

Kromhout D Giltay EJ Geleijnse JM . Alpha Omega trial G: n-3 Fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363: 2015–2026.

Yokoyama M Origasa H Matsuzaki M et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): A randomised open-label, blinded endpoint analysis. Lancet 2007; 369: 1090–1098.

Bhatt DL Steg PG Miller M et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med Epub ahead of print 10 November 2018. DOI: 10.1056/NEJMoa1812792.

Nicholls SJ Lincoff AM Bash D et al. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol 2018; 41: 1281–1288.

Hidenori A, Sasaki J, Yokote K, et al. Ezetemibe in Prevention of Cerebro- and Cardiovascular Events in Middle- to High-Risk, Elderly (75 years or over) Patients With Elevated Cholesterol: A Multicenter, Randomized, Controlled, Open-Label Trial. American Heart Association Scientific Sessions 2018: Abstract 17581.

Schwartz GG Steg PG Szarek M et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med Epub ahead of print 29 November 2018. DOI: 10.1056/NEJMoa1801174.

Bhatt DL, Briggs A, Reed SD, et al. Cost-Effectiveness of Alirocumab Based on Evidence From a Large Multinational Outcome Trial: The ODYSSEY OUTCOMES Economics Study. American Heart Association Scientific Sessions 2018: Abstract 19490.

Tsimikas S, Karwatowska-Prokopczuk E, Gouni-Berthold I, et al. Safety and Efficacy of AKCEA-APO(a)-LRx to Lower Lipoprotein(a) Levels in Patients With Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial. American Heart Association Scientific Sessions 2018: Abstract 19497.

Marso SP Daniels GH Brown-Frandsen K et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016; 375: 311–322.

Zinman B Wanner C Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128.

Neal B Perkovic V Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657.

Wiviott SD Raz I Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med Epub ahead of print 10 November 2018. DOI: 10.1056/NEJMoa1812389.

Ridker PM Everett BM Thuren T et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119–1131.

Ross R . Atherosclerosis–an inflammatory disease. N Engl J Med 1999; 340: 115–126.

Ridker PM Everett BM Pradhan A et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med Epub ahead of print 10 November 2018. DOI: 10.1056/NEJMoa1809798.